WRF
RVNC

Waddell & Reed Financial’s Revance Therapeutics, Inc. RVNC Stock Holding History

Waddell & Reed Financial’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-63,900
Closed -$1.59M – 563
2018
Q3 		$1.59M Hold
63,900
– – ﹤0.01% 524
2018
Q2 		$1.75M Hold
63,900
– – ﹤0.01% 517
2018
Q1 		$1.97M Hold
63,900
– – ﹤0.01% 498
2017
Q4 		$2.28M Sell
63,900
-140,750
-69% -$4.04M 0.01% 496
2017
Q3 		$5.64M Sell
204,650
-19,250
-9% -$467K 0.01% 460
2017
Q2 		$5.91M Sell
223,900
-11,100
-5% -$248K 0.01% 475
2017
Q1 		$4.89M Sell
235,000
-15,000
-6% -$308K 0.01% 482
2016
Q4 		$5.17M Sell
250,000
-50,000
-17% -$837K 0.01% 485
2016
Q3 		$4.86M Hold
300,000
– – 0.01% 520
2016
Q2 		$4.08M Sell
300,000
-53,850
-15% -$952K 0.01% 512
2016
Q1 		$6.18M Sell
353,850
-217,000
-38% -$4.42M 0.01% 458
2015
Q4 		$19.5M Buy
570,850
+194,700
+52% +$6.75M 0.03% 319
2015
Q3 		$11.2M Buy
376,150
+65,800
+21% +$2M 0.02% 392
2015
Q2 		$9.93M Sell
310,350
-25,000
-7% -$643K 0.01% 437
2015
Q1 		$6.95M Sell
335,350
-13,700
-4% -$237K 0.01% 472
2014
Q4 		$5.91M Sell
349,050
-27,100
-7% -$473K 0.01% 475
2014
Q3 		$7.27M Sell
376,150
-4,526
-1% -$118K 0.01% 451
2014
Q2 		$12.9M Sell
380,676
-149,081
-28% -$4.67M 0.02% 397
2014
Q1 		$16.7M Buy
+529,757
New +$16.6M 0.03% 358

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

Waddell & Reed Financial's RVNC Position: Q4 2018 in Review

Waddell & Reed Financial sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2018, closing a stake of 63,900 shares — an estimated $1.59M sold.

Waddell & Reed Financial first reported a position in RVNC in Q1 2014 and held it in 19 quarters. The position peaked at $19.5M in Q4 2015. 101 funds tracked by Wall St. Rank hold RVNC as of Q4 2018.

  • Waddell & Reed Financial reported no remaining Revance Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • Waddell & Reed Financial sold 63,900 Revance Therapeutics, Inc. shares in Q4 2018, an estimated $1.59M.
  • Waddell & Reed Financial first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 19 quarters.
  • Waddell & Reed Financial's Revance Therapeutics, Inc. position peaked at $19.5M in Q4 2015.
  • 101 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2018.

Based on Waddell & Reed Financial's 13F filing for Q4 2018, filed 14 Feb 2019.